Expert Insights

Diana Osorio, MD, MPH, MD Anderson Cancer Center

Videos

Targeting BRAF V600E in Pediatric Cervicomedullary Ganglioglioma

09/18/2026

Diana Osorio, MD, MPH

Diana Osorio, MD, MPH, discusses the clinical significance of BRAF V600E in pediatric cervicomedullary ganglioglioma, highlighting the role of molecular profiling in guiding BRAF/MEK-targeted therapy and the practical considerations of...

Diana Osorio, MD, MPH, discusses...

09/18/2026

Oncology

Sponsored

Videos

Bone Marrow Biopsy at a Glance: Manual and Powered Techniques—Lessons From Practice

09/10/2026

Bryon Allen, FNP; Jeremy Heinerich, PA-C

09/10/2026

Oncology

Sponsored

Videos

Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World Practice

09/08/2026

Beth Faiman, CNP, PhD

09/08/2026

Oncology

Videos

Zanidatamab-Based Regimens Redefine First-Line Treatment of HER2-Positive Gastroesophageal Adenocarcinoma

09/08/2026

Geoffrey Ku, MD

Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...

Geoffrey Ku, MD, discusses...

09/08/2026

Oncology

Podcasts

Preparing for Biomarker-Directed Care in epNEC: What Pathologists Need to Know Now

09/03/2026

David Klimstra, MD

This podcast features Dr David Klimstra discussing how pathologists can prepare for biomarker-directed care in extrapulmonary neuroendocrine carcinoma (epNEC). Key topics include accurate NEC classification before delta-like ligand 3 (DLL3)...

This podcast features Dr David...

09/03/2026

Oncology

Videos

Nivolumab Plus Ipilimumab Fails to Overcome Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma

09/02/2026

Viktor Grünwald, MD, PhD

Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...

Viktor Grünwald, MD, PhD,...

09/02/2026

Oncology

Videos

Statin-Specific Effects May Influence Immunotherapy Outcomes in Patients With Head and Neck Squamous Cell Carcinoma

09/02/2026

Allen Khudaverdyan, MD

Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...

Allen Khudaverdyan, MD,...

09/02/2026

Oncology

Videos

Perioperative Pembrolizumab May Not Be Cost-Effective in Advanced Head and Neck Cancer

09/02/2026

Christopher Noel, MD, PhD

Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...

Christopher Noel, MD, PhD,...

09/02/2026

Oncology

Sponsored

Videos

Planning for Success: Supporting Patients on BESREMi

09/01/2026

Beth Faiman, CNP, PhD

Dr Beth Faiman discusses practical strategies for patient counseling, monitoring, and adverse event management to support long-term treatment persistence in polycythemia vera.

Dr Beth Faiman discusses...

09/01/2026

Oncology

Sponsored

Videos

What Long-Term BESREMi Data Show in PV

09/01/2026

Rami Komrokji, MD

Dr Rami Komrokji reviews long-term efficacy and safety data in polycythemia vera, highlighting durability of response, phlebotomy reduction, and sustained disease control.

Dr Rami Komrokji reviews...

09/01/2026

Oncology

Recent News

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology

News

Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

09/15/2026

Emily Estrada

Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...

Topline results from the phase 3...

09/15/2026

Oncology

News

GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia

09/15/2026

Emily Estrada

Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...

Real-world findings associated...

09/15/2026

Oncology

News

Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia

09/15/2026

Emily Estrada

Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...

Extended results from the phase...

09/15/2026

Oncology

News

Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms

09/15/2026

Emily Estrada

Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...

Results from a real-world study...

09/15/2026

Oncology